Stay updated with breaking news from Cost Effectiveness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts discuss the landscape of treatment options for Duchenne muscular dystrophy, examine the benefits and risks of gene therapy and conventional steroid treatments, and emphasize the need for early intervention and comprehensive care.
Fe electrocoagulation technology was proposed for roxarsone (3-nitro-4-hydroxyphenyl-arsonic acid, ROX) removal from water. The effects of current density (CD) and initial pH on ROX removal and operating costs were evaluated using batch tests. Results showed a high total arsenic (TAs) removal efficiency (≥ 99.5 %) at 40 min (CD 1.75–8.77 A/m2, pH 4.6–8.6). Sludge treatment cost accounted for the highest proportion of total operating costs. High concentrations of HCO3− and humic acid had significant inhibition impacts on TAs removal. Hydroxyl radicals (•OH) were mainly responsible for...
SCG presents solutions aimed at enhancing business value and reducing costs for hotel groups, banquet halls, office buildings, hospitals, educational institutions, and industrial factories. These solutions cover various business needs, ensuring
Emma Ciafaloni, MD, FAAN, explores the groundbreaking approval of onasemnogene abeparvovec-xioi for spinal muscular atrophy and its impact on the treatment paradigm for this rare disease.
Ryan Haumschild, PharmD, MS, MBA, and Mary Pak, MD, FACP, consider FDA-approved gene therapies for hemophilia, spinal muscular atrophy, and Duchenne muscular dystrophy, exploring their genetic foundations, the FDA approval process, and considerations for therapeutic value and cost.